生物
PI3K/AKT/mTOR通路
mTOR抑制剂的发现与发展
癌症研究
细胞生长
羟基化
RPTOR公司
腺癌
肺
癌变
细胞生物学
内科学
信号转导
癌症
生物化学
遗传学
酶
医学
作者
Ersuo Jin,Shengjie Wang,Donglai Chen,Jia-Ping Wang,Yuanyuan Zeng,Runfeng Sun,Hongtao Zhang
出处
期刊:Oncogene
[Springer Nature]
日期:2024-04-23
卷期号:43 (24): 1813-1823
被引量:10
标识
DOI:10.1038/s41388-024-03032-1
摘要
Abstract, Mammalian target of rapamycin (mTOR) kinase functions as a central regulator of cell growth and metabolism, and its complexes mTORC1 and mTORC2 phosphorylate distinct substrates. Dysregulation of mTOR signaling is commonly implicated in human diseases, including cancer. Despite three decades of active research in mTOR, much remains to be determined. Here, we demonstrate that prolyl 4-hydroxylase alpha-2 (P4HA2) binds directly to mTOR and hydroxylates one highly conserved proline 2341 (P2341) within a kinase domain of mTOR, thereby activating mTOR kinase and downstream effector proteins (e.g. S6K and AKT). Moreover, the hydroxylation of P2341 strengthens mTOR stability and allows mTOR to accurately recognize its substrates such as S6K and AKT. The growth of lung adenocarcinoma cells overexpressing mTOR P2341A is significantly reduced when compared with that of cells overexpressing mTOR WT . Interestingly, in vivo cell growth assays show that targeting P4HA2-mTOR significantly suppresses lung adenocarcinoma cell growth. In summary, our study reveals an undiscovered hydroxylation-regulatory mechanism by which P4HA2 directly activates mTOR kinase, providing insights for therapeutically targeting mTOR kinase-driven cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI